



(51) International Patent Classification:

A61K 31/5377 (2006.01) A61K 31/4706 (2006.01)
A61K 31/4709 (2006.01)

(21) International Application Number:

PCT/US2016/063353

(22) International Filing Date:

22 November 2016 (22.11.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/259,828 25 November 2015 (25.11.2015) US
62/334,149 10 May 2016 (10.05.2016) US

(71) Applicant: **EFFECTOR THERAPEUTICS, INC.**
[US/US]; 11180 Roselle Street, San Diego, CA 92121 (US).(72) Inventors: **ERNST, Justin, T.**; 4288 Kerwood Court, San Diego, CA 92130 (US). **REICH, Siegfried, H.**; 5940 La Jolla Mesa Drive, La Jolla, CA 92037 (US). **SPRENGEL-ER, Paul, A.**; 8706 Gracilior Court, Escondido, CA 92026 (US). **TRAN, Chinh**; 2736 Bellezza Drive, San Diego, CA 92108 (US). **PACKARD, Garrick, Kenneth**; 4485 Vision Dr Apt. 6, San Diego, CA 92121 (US). **XIANG, Alan, Xin**; 211 Midvale Lane, Irvine, CA 92620 (US).

NILEWSKI, Christian; 5940 La Jolla Mesa Drive, La Jolla, CA 92037 (US). **MICHEL, Theodore**; 4353 Felton St. #3, San Diego, CA 92104 (US).


(74) Agent: **PINO, Mark, J.**; Mintz Levin Cohn Ferris Glovsky And Popeo, PC, 701 Pennsylvania Avenue, Nw, Suite 900, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO



(I)

(57) Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula (I) compounds X, Y, R¹, R², R^{3a}, R^{3b}, R^{4a}, R^{4b} and R⁵ are as defined in the specification. The inventive Formula (I) compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, —
GW, KM, ML, MR, NE, SN, TD, TG).

*before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*